Viz.ai and Cleerly Partner on AI-Powered Heart Disease Evaluation Technology

September 12, 2024—Viz.ai and Cleerly recently announced a partnership to bring Cleerly into the Viz.ai One platform to improve and expedite the coordination of care for patients with heart disease.

Viz.ai is focused on artificial intelligence (AI)–powered disease detection and intelligent care coordination. Cleerly is focused on the diagnosis of heart disease.

According to the companies, the Viz.ai One platform continues to expand its suite of AI-powered capabilities for cardiology, including advanced features such as electrocardiogram (ECG) AI; echocardiogram (echo) AI; chest CT visualization and AI; team activation; and HIPAA-compliant communication.

The press release stated that Cleerly has developed several FDA-approved softwares that use coronary CT angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and categorize plaque.

“I am especially excited about the potential of this partnership between Viz.ai and Cleerly to transform the earlier management of patients with heart disease,” commented Jonathan Aliota, MD, in the companies’ press release. Dr. Aliota, who is an interventional cardiologist at Kelsey-Seybold Clinic in Houston, Texas, continued, “AI-powered automated detection of heart disease-associated ischemia will streamline diagnosis and facilitate timely specialist referrals, ultimately enhancing access to life-saving treatments and improving patient outcomes.”